Heat Biologics plans to price $12.5 million public offering of stock

Bookrunner Roth Capital helps fund clinical trials, corporate purposes

By Devika Patel

Knoxville, Tenn., Jan. 21 – Heat Biologics, Inc. will conduct a $12.5 million public sale of common stock with a 45-day $1,875,000 greenshoe, according to a preliminary prospectus supplement filed Thursday with the Securities and Exchange Commission.

Roth Capital Partners is the bookrunner.

Proceeds will be used for clinical trials and general corporate purposes.

The biopharmaceutical company is based in Durham, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.